Valuation: DMS

Market Cap 2.35Cr 2.62Cr 2.16Cr 1.96Cr 3.66Cr 248.97Cr 3.73Cr 26Cr 10Cr 130.97Cr 9.84Cr 9.63Cr 413.02Cr P/E 2026 *
45.4x
P/E 2027 * 10.1x
Enterprise Value 4.19Cr 4.68Cr 3.85Cr 3.49Cr 6.53Cr 444.05Cr 6.65Cr 46Cr 18Cr 233.58Cr 18Cr 17Cr 736.63Cr EV / Sales 2026 *
0.93x
EV / Sales 2027 * 0.57x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.62Cr
-1.72%+3.44%+25.31%+60.56% 26TCr
-2.00%+0.75%+7.99%+25.46% 16TCr
-3.73%-4.48%-18.49%+67.13% 15TCr
-1.66%-8.12%-58.26%-16.12% 6.08TCr
-2.57%+3.30%+10.22%+47.55% 5.3TCr
0.00%+2.46%-11.97%-6.29% 5.33TCr
-3.47%+1.04%+21.98%+72.85% 4.93TCr
+0.84%-3.12%+9.80%+64.47% 5.07TCr
-3.61%+1.99%+34.94%+95.49% 4.55TCr
Average -1.79%-0.30%+2.39%+45.68% 9.82TCr
Weighted average by Cap. -2.10%+0.15%+5.19%+47.79%

Financials

2026 *2027 *
Net sales 4.49Cr 5.01Cr 4.13Cr 3.74Cr 7Cr 476.03Cr 7.13Cr 49Cr 20Cr 250.4Cr 19Cr 18Cr 789.68Cr 6Cr 6.7Cr 5.52Cr 5Cr 9.35Cr 636.11Cr 9.52Cr 66Cr 26Cr 334.61Cr 25Cr 25Cr 1.06TCr
Net income 4L 4L 4L 3L 6L 4.24Cr 6L 43.88L 17.61L 2.23Cr 16.76L 16.41L 7.04Cr 23L 25.68L 21.16L 19.17L 35.83L 24Cr 36.5L 2.52Cr 1.01Cr 13Cr 96.38L 94.33L 40Cr
Net Debt 1.84Cr 2.05Cr 1.69Cr 1.53Cr 2.87Cr 195.08Cr 2.92Cr 20Cr 8.1Cr 102.62Cr 7.71Cr 7.55Cr 323.61Cr 1.09Cr 1.22Cr 1Cr 90.85L 1.7Cr 115.56Cr 1.73Cr 12Cr 4.8Cr 61Cr 4.57Cr 4.47Cr 191.7Cr
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - DMS